

REGENERON PHARMACEUTICALS INC
Form 4
December 20, 2012

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
McCorkle Douglas S

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON
PHARMACEUTICALS INC
[REGN]

3. Date of Earliest Transaction (Month/Day/Year)
12/18/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
VP Controller & Asst Treasurer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	12/18/2012		M ⁽¹⁾	3,873 A	\$ 21.25	7,873	D
Common Stock	12/18/2012		F ⁽¹⁾	460 D	\$ 178.62	7,413	D
Common Stock	12/18/2012		F ⁽¹⁾	1,572 D	\$ 178.62	5,841	D
Common Stock	12/18/2012		M ⁽¹⁾	152 A	\$ 21.25	5,993	D
	12/18/2012		S ⁽¹⁾	152 D		5,841	D

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock						\$ 180.36			
Common Stock	12/18/2012		M ⁽¹⁾	300	A	\$ 21.25	6,141	D	
Common Stock	12/18/2012		S ⁽¹⁾	300	D	\$ 179.51 (2)	5,841	D	
Common Stock	12/18/2012		M ⁽¹⁾	100	A	\$ 21.25	5,941	D	
Common Stock	12/18/2012		S ⁽¹⁾	100	D	\$ 178.46	5,841	D	
Common Stock	12/18/2012		M ⁽¹⁾	200	A	\$ 21.25	6,041	D	
Common Stock	12/18/2012		S ⁽¹⁾	200	D	\$ 177.46 (3)	5,841	D	
Common Stock	12/19/2012		S ⁽¹⁾	1,000	D	\$ 174.52 (4)	4,841	D	
Common Stock	12/19/2012		S ⁽¹⁾	541	D	\$ 175.53 (5)	4,300	D	
Common Stock	12/19/2012		S ⁽¹⁾	100	D	\$ 176.46	4,200	D	
Common Stock	12/19/2012		S ⁽¹⁾	100	D	\$ 177.83	4,100	D	
Common Stock	12/19/2012		S ⁽¹⁾	100	D	\$ 180.75	4,000	D	
Common Stock							4,008	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--	---	--------------------------------------	--	--------------------------------	--	--	---

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Represents volume-weighted average price of sales of 200 shares of Company stock on December 18, 2012 at prices ranging from \$177.22 to \$177.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 18, 2012 at each separate price.

- (4) Represents volume-weighted average price of sales of 1,000 shares of Company stock on December 19, 2012 at prices ranging from \$174.06 to \$174.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 19, 2012 at each separate price.

- (5) Represents volume-weighted average price of sales of 541 shares of Company stock on December 19, 2012 at prices ranging from \$175.11 to \$175.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 19, 2012 at each separate price.

- (6) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

- (7) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.